GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolva Holding SA (XSWX:EVE) » Definitions » EV-to-FCF

Evolva Holding (XSWX:EVE) EV-to-FCF : -1.58 (As of Apr. 26, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Evolva Holding EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Evolva Holding's Enterprise Value is CHF19.63 Mil. Evolva Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-12.40 Mil. Therefore, Evolva Holding's EV-to-FCF for today is -1.58.

The historical rank and industry rank for Evolva Holding's EV-to-FCF or its related term are showing as below:

XSWX:EVE' s EV-to-FCF Range Over the Past 10 Years
Min: -25.02   Med: -4.46   Max: -0.33
Current: -1.54

During the past 13 years, the highest EV-to-FCF of Evolva Holding was -0.33. The lowest was -25.02. And the median was -4.46.

XSWX:EVE's EV-to-FCF is ranked worse than
100% of 393 companies
in the Biotechnology industry
Industry Median: 4.27 vs XSWX:EVE: -1.54

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Evolva Holding's stock price is CHF1.01. Evolva Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-20.600. Therefore, Evolva Holding's PE Ratio for today is At Loss.


Evolva Holding EV-to-FCF Historical Data

The historical data trend for Evolva Holding's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolva Holding EV-to-FCF Chart

Evolva Holding Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.29 -6.97 -5.26 -3.97 -4.80

Evolva Holding Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.97 - -4.80 -

Competitive Comparison of Evolva Holding's EV-to-FCF

For the Biotechnology subindustry, Evolva Holding's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolva Holding's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolva Holding's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Evolva Holding's EV-to-FCF falls into.



Evolva Holding EV-to-FCF Calculation

Evolva Holding's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=19.626/-12.402
=-1.58

Evolva Holding's current Enterprise Value is CHF19.63 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Evolva Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-12.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evolva Holding  (XSWX:EVE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Evolva Holding's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.01/-20.600
=At Loss

Evolva Holding's share price for today is CHF1.01.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Evolva Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-20.600.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Evolva Holding EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Evolva Holding's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolva Holding (XSWX:EVE) Business Description

Traded in Other Exchanges
Address
Duggingerstrasse 23, Reinach, CHE, CH-4153
Evolva Holding SA en liquidation formerly Evolva Holding SA is a biotechnology company. The company is engaged in discovering, developing, and commercializing ingredients and biomanufacturing processes for nutrition, healthcare, and wellness products. Geographically, the company operates in Switzerland and the United States where Switzerland derives a majority of its revenue.